Meghan E Sise1, Jamie S Hirsch, Pietro A Canetta, Leal Herlitz, Sumit Mohan. 1. aDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts bDivision of Nephrology, Department of Medicine cDepartment of Biomedical Informatics, Columbia University Medical Center, New York, New York dDepartment of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
OBJECTIVE: Tenofovir disoproxil fumarate (TDF) nephrotoxicity is characterized by proximal renal tubular injury and dysmorphic mitochondria resulting in proteinuria, orthoglycemic glycosuria, and other markers of proximal tubular dysfunction. The objective of this study was to determine the pattern of proteinuria in patients with biopsy-proven TDF nephrotoxicity. DESIGN: Retrospective chart review. METHODS: Patients with biopsy-proven TDF nephrotoxicity were identified and their medical charts and biopsy reports were reviewed. Comparison was made with HIV-infected patients not on TDF who underwent kidney biopsy. RESULTS: We identified 43 biopsy-proven cases of TDF nephrotoxicity; mean age 54.7 ± 0.4 years, 53% men, 42% whites. Thirty-seven cases reported proteinuria by dipstick of which only 60% had at least 2+ proteinuria. Twenty-seven patients had urine protein quantified by either 24-h collection or spot urine protein-to-creatinine ratio; median proteinuria was 1742 mg/day [interquartile range (IQR) 1200-2000 mg] and 1667 mg/g creatinine (IQR 851-1967 mg/g), respectively. Ten patients had concurrent urinary albumin measured, with a median 236 mg/g creatinine (IQR 137-343 mg/g). The mean urine albumin-to-urine protein ratio (uAPR) was 0.17 (IQR 0.14-0.19), confirming that TDF nephrotoxicity is primarily associated with nonalbumin proteinuria. Control cases had a uAPR of 0.65 (IQR 0.55-0.79) P < 0.001. Histopathology showed the predominance of proximal tubular injury with characteristic mitochondrial abnormalities. CONCLUSION: In the largest published cohort of patients with biopsy-proven TDF nephrotoxicity, we show that low uAPR is a reliable feature of this disease. Because of the predominance of nonalbumin proteinuria, dipstick urinalysis may be unreliable in TDF nephrotoxicity.
OBJECTIVE:Tenofovir disoproxil fumarate (TDF) nephrotoxicity is characterized by proximal renal tubular injury and dysmorphic mitochondria resulting in proteinuria, orthoglycemic glycosuria, and other markers of proximal tubular dysfunction. The objective of this study was to determine the pattern of proteinuria in patients with biopsy-proven TDF nephrotoxicity. DESIGN: Retrospective chart review. METHODS:Patients with biopsy-proven TDF nephrotoxicity were identified and their medical charts and biopsy reports were reviewed. Comparison was made with HIV-infectedpatients not on TDF who underwent kidney biopsy. RESULTS: We identified 43 biopsy-proven cases of TDF nephrotoxicity; mean age 54.7 ± 0.4 years, 53% men, 42% whites. Thirty-seven cases reported proteinuria by dipstick of which only 60% had at least 2+ proteinuria. Twenty-seven patients had urine protein quantified by either 24-h collection or spot urine protein-to-creatinine ratio; median proteinuria was 1742 mg/day [interquartile range (IQR) 1200-2000 mg] and 1667 mg/g creatinine (IQR 851-1967 mg/g), respectively. Ten patients had concurrent urinary albumin measured, with a median 236 mg/g creatinine (IQR 137-343 mg/g). The mean urine albumin-to-urine protein ratio (uAPR) was 0.17 (IQR 0.14-0.19), confirming that TDF nephrotoxicity is primarily associated with nonalbumin proteinuria. Control cases had a uAPR of 0.65 (IQR 0.55-0.79) P < 0.001. Histopathology showed the predominance of proximal tubular injury with characteristic mitochondrial abnormalities. CONCLUSION: In the largest published cohort of patients with biopsy-proven TDF nephrotoxicity, we show that low uAPR is a reliable feature of this disease. Because of the predominance of nonalbumin proteinuria, dipstick urinalysis may be unreliable in TDF nephrotoxicity.
Authors: Kerry M Sheets; Mohamed G Atta; Derek M Fine; Katie Zook; Allison M Mcfall; Michelle M Estrella; George J Schwartz; Gregory M Lucas Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: Kedar Joshi; David Boettiger; Stephen Kerr; Takeshi Nishijima; Kinh Van Nguyen; Penh Sun Ly; Man Po Lee; Nagalingeswaran Kumarasamy; Wingwai Wong; Pacharee Kantipong; Do Duy Cuong; Adeeba Kamarulzaman; Jun Yong Choi; Fujie Zhang; Romanee Chaiwarith; Oon Tek Ng; Sasisopin Kiertiburanakul; Benedict Lim Heng Sim; Tuti Parwati Merati; Evy Yunihastuti; Rossana Ditangco; Jeremy Ross; Sanjay Pujari Journal: Pharmacoepidemiol Drug Saf Date: 2018-09-24 Impact factor: 2.890
Authors: Simon B Ascher; Rebecca Scherzer; Michelle M Estrella; William R Zhang; Anthony N Muiru; Vasantha Jotwani; Carl Grunfeld; Chirag R Parikh; Deborah Gustafson; Mary Young; Anjali Sharma; Mardge H Cohen; Derek K Ng; Frank J Palella; Mallory D Witt; Ken Ho; Michael G Shlipak Journal: Clin J Am Soc Nephrol Date: 2018-08-28 Impact factor: 8.237
Authors: S B Ascher; R Scherzer; M M Estrella; A N Muiru; V K Jotwani; C Grunfeld; J Shigenaga; K A Spaulding; D K Ng; D Gustafson; A B Spence; A Sharma; M H Cohen; C R Parikh; J H Ix; M G Shlipak Journal: HIV Med Date: 2021-03-09 Impact factor: 3.094
Authors: David R Chadwick; Fred S Sarfo; Elaine S M Kirk; Dorcas Owusu; George Bedu-Addo; Victoria Parris; Ann Lorraine Owusu; Richard Phillips Journal: BMC Nephrol Date: 2015-12-01 Impact factor: 2.388
Authors: G Emerens Wensink; Annelot F Schoffelen; Hugo A Tempelman; Maarten B Rookmaaker; Andy I M Hoepelman; Roos E Barth Journal: PLoS One Date: 2015-08-26 Impact factor: 3.240